Engineering and Evaluation of Human L-Methionase for Cancer Therapy

人类 L-甲硫氨酸酶用于癌症治疗的工程和评估

基本信息

  • 批准号:
    8023816
  • 负责人:
  • 金额:
    $ 44.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-01-01 至 2014-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Neuroblastoma is the most common extra-cranial solid tumor of childhood with an appalling 30% cure rate in children with advanced disease. There is a clear need for new chemotherapeutics, as current drugs are only marginally effective at the high doses that result in toxic acute and grave long term side effects. The overall objective of this proposal is to employ modern techniques of protein engineering to develop a new generation of non-immunogenic and pharmacologically optimized enzymes for chemotherapy of neuroblastomas and other central nervous system (CNS) cancers through L-Methionine (L-Met) depletion. L-Met is required not only for protein synthesis but also as the precursor for methylation reductions and for the biosynthesis of polyamines. Tumors have a much greater requirement for L-Met than normal tissues and become apoptotic when its availability is restricted. i.v. administration of bacterial (Pseudomonas) methionine-g-lyase is able to mediated near complete depletion of L-Met in serum and has been shown to drastically inhibit tumor growth of neuroblastomas, glioblastomas and prostate carcinomas in mouse xeongrafts. Furthermore strong synergistic effects with microtubule depolymerization agents have been reported. Unfortunately, in clinical trials the bacterial enzyme was shown to have very poor pharmacological properties (t 1/2 in serum only 2 hrs) and was found to be highly immunogenic in primates eliciting severe adverse responses that resulted in anaphylactic shock and death. While the human genome does not encode any methionine lyase enzymes, in preliminary studies we deployed protein engineering strategies to generate potentially non-immunogenic variants of the human enzyme cystathionine-g-lyase that: (a) exhibit high L-Met degradation activity in vitro and in vivo, (b) display a lower IC50 for neuroblastoma cell lines than their bacterial counterparts and (c) are about 10-fold more stable in mice. Here we will employ structure guided mutagenesis and directed evolution strategies to: 1. Engineer catalytically optimized "human L-methioninases" i.e. cystathionine-g-lyase enzymes with very high activity for L-Met degradation, even better stability in serum and high selectivity. 2. Develop optimized formats of the "human L-methioninases" for prolonged persistence in circulation by either site-specific PEGylation or by fusion to long intrinsically disordered polypeptide sequences (XTEN) and determine their pharmacokinetic and pharmacodynamic properties. 3. Evaluate the efficacy of these enzymes in the mouse xenograft model of human neuroblastoma tumors formed using clinical cell lines established either in diagnosis or relapse. The utility of these enzymes will be investigated both as monotherapy and in combination therapy with vincristine. PUBLIC HEALTH RELEVANCE: Neuroblastoma is the most common extra-cranial solid tumor of childhood with an appalling 30% cure rate in children with advanced disease. There is a clear need for new chemotherapeutics, as current drugs are only marginally effective at the high doses that result in toxic acute and grave long term side effects. We are developing a drug engineered from a human enzyme that can kill tumors as a single agent by attacking a key metabolic point of neuroblastoma cells and is showing fantastic promise when used in combination with low non-toxic doses of current chemotherapeutics.
描述(申请人提供):神经母细胞瘤是儿童最常见的颅外实体瘤,在晚期儿童中治愈率高达30%。显然需要新的化疗药物,因为目前的药物在高剂量下只有微弱的效果,会导致急性毒性和严重的长期副作用。本课题的总体目标是利用现代蛋白质工程技术开发新一代非免疫原性和药理学优化的酶,用于通过l -蛋氨酸(L-Met)耗损治疗神经母细胞瘤和其他中枢神经系统(CNS)癌症。L-Met不仅是蛋白质合成所必需的,也是甲基化还原和多胺生物合成的前体。肿瘤对L-Met的需求量比正常组织大得多,当L-Met的可用性受到限制时,肿瘤就会发生凋亡。静脉注射细菌(假单胞菌)蛋氨酸裂解酶能够介导血清中L-Met的几乎完全消耗,并已被证明能显著抑制小鼠移植神经母细胞瘤、胶质母细胞瘤和前列腺癌的肿瘤生长。此外,还报道了与微管解聚剂的强协同效应。不幸的是,在临床试验中,细菌酶显示出非常差的药理学特性(在血清中只有2小时),并且在灵长类动物中发现高度免疫原性,引起严重的不良反应,导致过敏性休克和死亡。虽然人类基因组不编码任何蛋氨酸裂解酶,但在初步研究中,我们采用蛋白质工程策略来产生潜在的非免疫原性人类酶半胱硫氨酸-g-裂解酶的变体:(a)在体外和体内均表现出高的L-Met降解活性,(b)对神经母细胞瘤细胞系的IC50比其细菌对应物低,(c)在小鼠中的稳定性约为10倍。在这里,我们将采用结构引导诱变和定向进化策略:1。工程师催化优化的“人l -蛋氨酸酶”,即胱硫氨酸-g-裂解酶,具有很高的L-Met降解活性,在血清中具有更好的稳定性和高选择性。2. 通过位点特异性聚乙二醇化或与长内在无序多肽序列(XTEN)融合,开发“人类l -蛋氨酸酶”的优化格式,以延长循环的持久性,并确定其药代动力学和药效学特性。3. 评估这些酶在人类神经母细胞瘤小鼠异种移植模型中的作用,这些肿瘤是由临床细胞系形成的,无论是诊断还是复发。这些酶的效用将被研究作为单一治疗和与长春新碱联合治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEORGE Georgiou GEORGIOU其他文献

GEORGE Georgiou GEORGIOU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEORGE Georgiou GEORGIOU', 18)}}的其他基金

Systematic, molecular level analysis of the Fc receptor ligation on antibody effector functions
Fc 受体连接对抗体效应子功能的系统分子水平分析
  • 批准号:
    10533299
  • 财政年份:
    2019
  • 资助金额:
    $ 44.25万
  • 项目类别:
Systematic, molecular level analysis of the Fc receptor ligation on antibody effector functions
Fc 受体连接对抗体效应子功能的系统分子水平分析
  • 批准号:
    10308041
  • 财政年份:
    2019
  • 资助金额:
    $ 44.25万
  • 项目类别:
Development of antibody-based diagnostic assays for filoviruses
开发基于抗体的丝状病毒诊断方法
  • 批准号:
    8377064
  • 财政年份:
    2012
  • 资助金额:
    $ 44.25万
  • 项目类别:
Engineering and Evaluation of Human L-Methionase for Cancer Therapy
人类 L-甲硫氨酸酶用于癌症治疗的工程和评估
  • 批准号:
    8208991
  • 财政年份:
    2011
  • 资助金额:
    $ 44.25万
  • 项目类别:
Engineering and Evaluation of Human L-Methionase for Cancer Therapy
人类 L-甲硫氨酸酶用于癌症治疗的工程和评估
  • 批准号:
    8607840
  • 财政年份:
    2011
  • 资助金额:
    $ 44.25万
  • 项目类别:
Engineering and Evaluation of Human L-Methionase for Cancer Therapy
人类 L-甲硫氨酸酶用于癌症治疗的工程和评估
  • 批准号:
    8403663
  • 财政年份:
    2011
  • 资助金额:
    $ 44.25万
  • 项目类别:
Development of antibody-based diagnostic assays for filoviruses
开发基于抗体的丝状病毒诊断方法
  • 批准号:
    8301138
  • 财政年份:
    2011
  • 资助金额:
    $ 44.25万
  • 项目类别:
Human engineered enzymes for L-Arg depletion chemotherapy
用于 L-Arg 耗竭化疗的人类工程酶
  • 批准号:
    8039233
  • 财政年份:
    2009
  • 资助金额:
    $ 44.25万
  • 项目类别:
Human engineered enzymes for L-Arg depletion chemotherapy
用于 L-Arg 耗竭化疗的人类工程酶
  • 批准号:
    7636106
  • 财政年份:
    2009
  • 资助金额:
    $ 44.25万
  • 项目类别:
Interconversion of Specificity within Enzyme Families
酶家族内特异性的相互转换
  • 批准号:
    6859727
  • 财政年份:
    2005
  • 资助金额:
    $ 44.25万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 44.25万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 44.25万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 44.25万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了